Редактирование: CYP2R1

Vitamin D 25-hydroxylase precursor (EC 1.14.14.24) (Cytochrome P450 2R1)

==Publications==

{{medline-entry
|title=Decreased Serum 25-Hydroxyvitamin D in Aging Male Mice Is Associated With Reduced Hepatic Cyp2r1 Abundance.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/29955863
|abstract=The prevalence of vitamin D deficiency, as determined by circulating levels of 25-hydroxycalciferol [25(OH)D], is greater in older individuals compared with the young. To examine the hypothesis that altered production or inactivation of 25(OH)D contributes to lower circulating levels of 25(OH)D, we measured the serum levels of parent vitamin D3 (cholecalciferol) and 25(OH)D. We also determined the relative abundance of transcripts encoding hepatic [[CYP2R1]] and [[CYP27B1]], the principal 25-hydroxylases, transcripts encoding enzymes that degrade 25(OH)D in the liver (Cyp3A11) and kidney (Cyp24A1) and transcripts encoding megalin and cubilin, proteins critical to vitamin D resorption in the kidney in mice at three different ages. We observed a significant decline in the relative abundance of Cyp2R1 in the liver with aging (one-way ANOVA, P = 0.0077). Concurrent with the decrease in mRNA, a significant decline in hepatic [[CYP2R1]] protein (one-way ANOVA for trend, P = 0.007) and 25(OH)D (one-way ANOVA for trend, P = 0.002) and in the ratio of 25(OH)D3 to cholecalciferol (one-way ANOVA, P = 0.0003). By contrast, levels of the transcripts encoding Cyp3a11, Cyp24a1, and Cyp27b1 megalin and cubilin were unchanged with aging. A significant positive correlation was found between Cyp2r1 mRNA and 25(OH)D, and a stronger correlation was found between Cyp2r1 mRNA and the ratio of 25(OH)D3 to cholecalciferol. These results indicate that decreased expression of [[CYP2R1]] contributes to the reduced serum levels of 25(OH)D in aging.
|mesh-terms=* Aging
* Animals
* Cholecalciferol
* Cholestanetriol 26-Monooxygenase
* Cytochrome P-450 CYP3A
* Gene Expression
* Kidney
* Liver
* Low Density Lipoprotein Receptor-Related Protein-2
* Male
* Membrane Proteins
* Mice
* RNA, Messenger
* Receptors, Cell Surface
* Vitamin D
* Vitamin D Deficiency
* Vitamin D3 24-Hydroxylase

|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693043
}}
{{medline-entry
|title=Environmental and genetic determinants of vitamin D status among older adults in London, UK.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/26776442
|abstract=Despite the high prevalence of vitamin D deficiency among older adults in the UK, studies investigating the determinants of vitamin D status in this group are lacking. We conducted a cross-sectional study in 222 older adults living in sheltered accommodation in London, UK, who were screened for participation in a clinical trial of vitamin D supplementation for the prevention of acute respiratory infection. Details of potential demographic and lifestyle determinants of vitamin D status were collected by questionnaire and blood samples were taken for analysis of serum 25-hydroxyvitamin D (25[OH]D) concentration and DNA extraction. Fifteen single nucleotide polymorphisms (SNP) in 6 genes (DBP, [[DHCR7]], [[CYP2R1]], [[CYP27B1]], [[CYP24A1]], VDR) previously reported to associate with circulating 25(OH)D concentration were typed using Taqman allelic discrimination assays. Linear regression was used to identify environmental and genetic factors independently associated with serum 25(OH)D concentration. Mean serum 25(OH)D concentration was 42.7nmol/L (SD 22.0); 144/222 (64.9%) participants had serum 25(OH)D concentrations <50nmol/L. The following factors were independently associated with lower serum 25(OH)D concentration: non-white ethnicity (-8.6nmol/L, 95% CI -14.9 to -2.3, P=0.008); lack of vitamin D supplement consumption (-17.1nmol/L, 95% CI -23.3 to -10.9, P<0.001) vs. taking a daily supplement; sampling in Q1/January-March (-12.2nmol/L, 95% CI -21.5 to -2.9, P=0.01), and sampling in Q4/October-December (-10.3nmol/L, 95% CI -20.2 to -0.4, P=0.04) vs. sampling in Q3/July-September. None of the 15 SNP investigated independently associated with serum 25(OH)D concentration after correcting for multiple comparisons. In conclusion, vitamin D deficiency was highly prevalent among the older adults in this study; non-White ethnicity, lack of vitamin D supplement consumption and sampling in winter and spring independently associated with lower vitamin D status.
|mesh-terms=* 25-Hydroxyvitamin D3 1-alpha-Hydroxylase
* Aged
* Aged, 80 and over
* Aging
* Cholestanetriol 26-Monooxygenase
* Clinical Trials as Topic
* Cohort Studies
* Cross-Sectional Studies
* Cytochrome P450 Family 2
* DNA-Binding Proteins
* Diet
* Dietary Supplements
* Female
* Genetic Predisposition to Disease
* Humans
* London
* Male
* Middle Aged
* Oxidoreductases Acting on CH-CH Group Donors
* Polymorphism, Single Nucleotide
* Receptors, Calcitriol
* Seasons
* Transcription Factors
* Vitamin D
* Vitamin D Deficiency
* Vitamin D3 24-Hydroxylase
|keywords=* Ageing
* Diet
* Polymorphism
* Season
* Single nucleotide
* Vitamin D
|full-text-url=https://sci-hub.do/10.1016/j.jsbmb.2016.01.005
}}
{{medline-entry
|title=Late-onset hypogonadism: beyond testosterone.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/25248651
|abstract=Late-onset hypogonadism is defined as a combination of low testosterone (T) levels and typical symptoms and signs. A major area of uncertainty is whether T concentrations are always really sufficient to fully reflect Leydig cell (dys)function. Mild testicular alteration could be diagnosed only by additional biochemical markers, such as luteinizing hormone (LH) and 25-hydroxyvitamin D levels. These markers help in identifying the so-called "subclinical" hypogonadism (normal T, high LH levels). Patients with hypogonadism have frequently low levels of 25-hydroxyvitamin D due to impairment of the hydroxylating enzyme [[CYP2R1]] in the testis. However, no data have been published dealing with the best treatment option (cholecalciferol - the Vitamin D precursor, or calcidiol - 25-hydroxylated form of Vitamin D) in these patients. We studied 66 patients with classic hypogonadism (total T [TT] <12 nmol l-1 , LH ≥ 8 IU l-1 ) (n = 26) and subclinical hypogonadism (TT ≥ 12 nmol l-1 , LH ≥ 8 IU l-1 ) (n = 40) and low 25-hydroxyvitamin D (<50 nmol l-1 ). Subjects received cholecalciferol (5000 IU per week) (n = 20) or calcidiol (4000 IU per week) (n = 46), and 25-hydroxyvitamin D and parathyroid hormone (PTH) were evaluated after 3 months of therapy. Supplementation with calcidiol significantly increased 25-hydroxyvitamin D and significantly decreased PTH levels in both groups of men with hypogonadism (primary, n = 16 and subclinical, n = 30), whereas supplementation with cholecalciferol did not modify their levels. This study shows for the first time that the administration of the 25-hydroxylated form of Vitamin D (calcidiol), and not the administration of the precursor cholecalciferol, restores 25-hydroxyvitamin D levels in subjects with hypogonadism. 
|mesh-terms=* Adult
* Aging
* Biomarkers
* Calcifediol
* Cholecalciferol
* Eunuchism
* Humans
* Luteinizing Hormone
* Male
* Parathyroid Hormone
* Precision Medicine
* Testosterone
* Treatment Outcome
* Vitamin D

|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650463
}}